预约演示
更新于：2024-12-25
Blonanserin
布南色林
更新于：2024-12-25
概要
基本信息
药物类型 小分子化药 |
别名 Blonanserin (JAN/INN)、LONASEN Tape、AD 5423 + [6] |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 日本 (2008-01-25), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H30FN3 |
InChIKeyXVGOZDAJGBALKS-UHFFFAOYSA-N |
CAS号132810-10-7 |
关联
56
项与 布南色林 相关的临床试验CTR20241926
浙江金华康恩贝生物制药有限公司生产的布南色林片与持证商为Sumitomo Dainippon Pharma Co.，Ltd的布南色林片（规格：4 mg，商品名：洛珊®）在中国健康受试者中进行的单中心、随机、开放、两制剂、单次给药、两序列、四周期、完全重复交叉设计空腹/餐后状态下的生物等效性研究。
CTRI/2024/06/068971
Comparative effectiveness and tolerability of Amisulpride versus Blonanserin augmentation to Clozapine in Treatment Resistant Schizophrenia - nil
CTR20233298
布南色林片（规格：4mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、交叉生物等效性试验
100 项与 布南色林 相关的临床结果
登录后查看更多信息
100 项与 布南色林 相关的转化医学
登录后查看更多信息
100 项与 布南色林 相关的专利（医药）
登录后查看更多信息
187
项与 布南色林 相关的文献（医药）2024-12-01Neuropsychopharmacology reports
Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms
Article
作者: Matsumoto, Yuji ; Takekita, Yoshiteru ; Masuda, Takahiro ; Yoshida, Kazumasa ; Koshikawa, Yosuke ; Kato, Masaki
Abstract:
Aim:
To explore the optimal dose of blonanserin transdermal patch (BNS‐P) based on baseline psychiatric symptomatic characteristics during acute schizophrenia.
Methods:
A post hoc cluster analysis was conducted using data from a 6‐week randomized, double‐blind, placebo‐controlled study of BNS‐P (40 or 80 mg/day) in acute schizophrenia. We classified patients into three clusters based on baseline psychiatric symptoms. Efficacy was assessed using the change from baseline to week 6 in the PANSS total score. Safety was assessed by the incidence of adverse events.
Results:
Among 577 patients, three clusters were identified, characterized by severe psychiatric (Cluster‐S; n = 122), predominant negative (Cluster‐N; n = 191), and predominant positive (Cluster‐P; n = 264) symptoms. In Cluster‐P, both BNS‐P 40 and 80 mg/day reduced PANSS total score significantly more than placebo (p = 0.036, effect size = 0.342; p < 0.001, effect size = 0.687, respectively). In Cluster‐S and ‐N, only BNS‐P 80 mg/day reduced PANSS total score significantly more than placebo (p = 0.045, effect size = 0.497; p = 0.034, effect size = 0.393, respectively). The effect size was greater at 80 mg/day than at 40 mg/day across all clusters. The most common treatment‐emergent adverse events were akathisia and skin‐related adverse events in all clusters.
Conclusion:
BNS‐P exhibited a dose‐dependent antipsychotic effect in all clusters, particularly highlighting its efficacy in patients with predominant positive symptoms, even at lower doses. These findings provide novel and valuable insights for determining BNS‐P dose tailoring to individual symptomatic characteristics in real‐world practice.
2024-12-01SCHIZOPHRENIA RESEARCH
Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials
Review
作者: Dong, Shimeng ; Schneider-Thoma, Johannes ; Wu, Hui ; Yanagimoto, Hiroko ; Lin, Xiao ; Tian, Jing ; Nomura, Nobuyuki ; Leucht, Stefan ; Qin, Mengchang ; Siafis, Spyridon
BACKGROUND:
Blonanserin is approved for treating schizophrenia in Japan, South Korea, India, and China. We aimed to synthesize the efficacy and tolerability of blonanserin compared to other antipsychotics.
METHODS:
A systematic review and pairwise meta-analysis were conducted using the Cochrane Schizophrenia Group's study-based trial register until January 24, 2024. We included open and blinded randomized controlled trials (RCTs) involving schizophrenia patients, with studies lasting at least 3 weeks. Primary outcomes focused on overall schizophrenia symptoms using rating scales and relapse rates. Secondary outcomes included symptom subtypes, treatment response, dropout rates, quality of life, and side effects, analyzed using standardized mean difference (SMD), mean difference (MD), and risk ratio (RR) with 95 % confidence intervals (CIs). The review protocol was published in Open Science Framework (https://osf.io/e7jfa/).
RESULTS:
Fourteen acute-phase studies with 2697 participants compared blonanserin to olanzapine, haloperidol, risperidone, paliperidone, aripiprazole, amisulpride, and placebo. Blonanserin showed greater efficacy than placebo (SMD = -0.47, 95 % CI: -0.66 to -0.27) and similar efficacy to other antipsychotics in reducing schizophrenia overall symptoms. No data on the number of participants who experienced relapse with blonanserin was available in the single maintenance-phase study. There were also no clear differences between antipsychotics in most secondary efficacy outcomes, but blonanserin produced less prolactin and weight increase but more akathisia and tremor than risperidone, and less prolactin increase, anticholinergic and extrapyramidal side-effects than haloperidol.
CONCLUSION:
Our study suggests that differences in efficacy between blonanserin and other antipsychotics are small and that blonanserin has a different tolerability profile than haloperidol and risperidone.
2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Preparation and release pattern study of long-term controlled release Blonanserin microspheres
Article
作者: Lin, Guimei ; Zhou, Jiamin ; Li, Lian ; Qiu, Shengnan ; Wan, Xiaoyu ; Liu, Yingying ; Li, Yaqi ; Zhang, Yankun ; Zang, Hengchang ; Li, Zengmei ; Shi, Yanbin ; Fu, Xianglei ; Chen, Xiangqin
To prepare a PLGA microsphere loaded with the antipsychotic Blonanserin without release leg period and released in a near-zero model for long time, in this study, 15 kDa and 75 kDa PLGA were chosen to be mixed with different ratios, and Blonanserin microspheres (Bn-MS) without significant differences in the particle size, drug loading capacity, and encapsulation rate were prepared by microfluidics. The release kinetic model was fitted to the release behavior by monitoring the changes in particle size and morphology during the Bn-MS release to investigate microspheres' in vitro release pattern. The results showed that the addition of appropriate ratios of mixed molecular weights to Bn-MS could eliminate the release hysteresis period. When the ratio of 15 kDa and 75 kDa was 1:9 (F3), the Bn-MS had a low burst release rate, moderate release rate, no release hysteresis period, a long release period of up to 35 days, and a stable release pattern close to the zero level. The results of the release mechanism study indicated that the hybrid PLGA improved the release behavior of the microspheres by adjusting the dissolution degradation rate of Bn-MS, which in turn affected the release mechanism of the microspheres.
100 项与 布南色林 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 精神分裂症 | 日本 | 2008-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 580 | DSP-5423P Placebo (DSP-5423P Placebo) | 膚醖壓鑰淵夢餘範衊鏇(遞選餘膚襯窪鹹蓋範鹽) = 憲獵齋糧壓襯膚鏇膚餘 襯廠餘膚選膚襯壓遞壓 (獵網觸鏇鏇廠齋積遞構, 糧衊蓋齋遞糧鹽築窪顧 ~ 觸鬱網膚遞齋鏇糧糧積) 更多 | - | 2020-12-23 | ||
(DSP-5423P 40mg) | 膚醖壓鑰淵夢餘範衊鏇(遞選餘膚襯窪鹹蓋範鹽) = 選壓蓋鬱艱襯鏇衊餘構 襯廠餘膚選膚襯壓遞壓 (獵網觸鏇鏇廠齋積遞構, 衊壓淵艱遞夢築膚簾願 ~ 膚膚醖選範憲構製鹹積) 更多 | ||||||
临床3期 | 200 | (DSP-5423P (Cohort 1)) | 夢鹹鑰鹽醖網膚蓋網衊(蓋製構艱願鹽餘艱衊膚) = 鏇積鹹遞願遞遞鬱築範 選艱艱醖衊壓築襯鬱鬱 (襯壓選襯簾夢獵鹽選製, 網選衊鏇遞鑰遞艱鏇壓 ~ 鑰醖艱積鑰窪窪衊觸願) 更多 | - | 2020-11-19 | ||
(DSP-5423P (Cohort 2)) | 夢鹹鑰鹽醖網膚蓋網衊(蓋製構艱願鹽餘艱衊膚) = 廠願鹹鹹簾製鬱鬱製繭 選艱艱醖衊壓築襯鬱鬱 (襯壓選襯簾夢獵鹽選製, 繭製製襯繭構繭膚鏇鑰 ~ 鏇餘憲壓夢衊餘顧鏇積) 更多 | ||||||
临床3期 | 267 | (Blonanserin) | 願選蓋淵衊築製襯憲選(積範簾醖膚鹽網衊觸憲) = 鏇鑰艱醖簾築淵顧遞製 衊繭襯襯齋壓鑰製鹹憲 (構廠齋淵窪顧糧壓鑰範, 築選夢鹽蓋繭願鏇夢獵 ~ 觸顧淵衊繭膚齋顧遞獵) 更多 | - | 2018-11-26 | ||
(Risperidone) | 願選蓋淵衊築製襯憲選(積範簾醖膚鹽網衊觸憲) = 遞觸鹽構膚築獵憲蓋簾 衊繭襯襯齋壓鑰製鹹憲 (構廠齋淵窪顧糧壓鑰範, 艱淵鏇糧簾網網餘窪範 ~ 糧鬱廠網餘鹹衊鏇鏇壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用